<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:hpo ids='HP_0003737'>Mitochondrial myopathy</z:hpo>, <z:hpo ids='HP_0001298'>encephalopathy</z:hpo>, <z:hpo ids='HP_0003128'>lactic acidosis</z:hpo> and <z:hpo ids='HP_0002401'>stroke-like episodes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MELAS</z:e>) is the most common type of <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> disease and is characterized by <z:hpo ids='HP_0002401'>stroke-like episodes</z:hpo> (SEs), <z:hpo ids='HP_0003198'>myopathy</z:hpo>, <z:hpo ids='HP_0003128'>lactic acidosis</z:hpo>, <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo>, hearing-loss and <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The causal hypotheses for SEs in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MELAS</z:e> presented to date are <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">angiopathy</z:e>, cytopathy and neuronal hyperexcitability </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="16467,29952">L-arginine</z:chebi> (Arg) has been applied for the therapy in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MELAS</z:e> patients </plain></SENT>
<SENT sid="3" pm="."><plain>SCOPE OF REVIEW: We will introduce novel in vivo functional brain imaging techniques such as MRI and PET, and discuss the pathogenesis of SEs in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MELAS</z:e> patients </plain></SENT>
<SENT sid="4" pm="."><plain>We will further describe here our clinical experience with L-arg therapy and discuss the dual pharmaceutical effects of this drug on <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MELAS</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>MAJOR CONCLUSIONS: Administration of L-arg to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MELAS</z:e> patients has been successful in reducing neurological symptoms due to <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001297'>strokes</z:hpo> and preventing recurrences of SEs in the <z:hpo ids='HP_0011010'>chronic</z:hpo> phase </plain></SENT>
<SENT sid="6" pm="."><plain>L-Arg has dual pharmaceutical effects on both <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">angiopathy</z:e> and cytopathy in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MELAS</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>GENERAL SIGNIFICANCE: In vivo functional brain imaging promotes a better understanding of the pathogenesis and potential therapies for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MELAS</z:e> patients </plain></SENT>
<SENT sid="8" pm="."><plain>This article is part of a Special Issue entitled Biochemistry of Mitochondria, Life and Intervention 2010 </plain></SENT>
</text></document>